Seqens

Ecully, France Founded: 2003 • Age: 23 yrs Acquired By SK Capital
Contract manufacturing services for small molecules and peptides are provided.
Request Access

About Seqens

Seqens is a company based in Ecully (France) founded in 2003 was acquired by SK Capital in December 2021.. The company has 39 employees as of April 07, 2024. Seqens has completed 2 acquisitions, including CELLforCURE and CU Chemie Uetikon. Seqens offers products and services including APIs and Intermediates, Personal Care Ingredients, and Custom Specialty Ingredients. Seqens operates in a competitive market with competitors including Almac Group, Indoco Remedies, Concord Biotech, BDR Pharmaceuticals Internationals and Aurobindo Pharma, among others.

  • Headquarter Ecully, France
  • Employees 39 as on 07 Apr, 2024
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Monolom India Pharma Private Limited
  • Date of Incorporation 27 Oct, 2017
  • Jurisdiction Pune, Maharashtra, India
Operational Areas
Healthcare → Healthcare Services & Infrastructure
Key Metrics
  • Annual Revenue
    $1.87 M (USD)
    19.92
    as on Mar 31, 2022
  • Net Profit
    $183.32 K (USD)
    21.7
    as on Mar 31, 2022
  • EBITDA
    $551.88 K (USD)
    1.58
    as on Mar 31, 2022
  • Latest Funding Round
  • Investors
    Eurazeo

    & 4 more

  • Employee Count
    39

    as on Apr 07, 2024

  • Investments & Acquisitions
    CELLforCURE

    & 1 more

  • Acquired by
    SK Capital

    (Dec 17, 2021)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Seqens

Seqens offers a comprehensive portfolio of products and services, including APIs and Intermediates, Personal Care Ingredients, and Custom Specialty Ingredients. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Manufacture generic and custom active pharmaceutical ingredients for industry use.

Wide range of ingredients for personal care market applications.

High-quality specialized chemical products for various applications.

People of Seqens
Headcount 1000-5000
Employee Profiles 38
Employee Profiles
People
Jean-Pierre Pilleux
Director Of Operations
People
Alexandra Ngawa Zenang
Business Line Manager Pharma Advanced Specialties BU
People
Ronan Rocle
Sales & Business Development Manager CDMO Scandinavia, Eastern Europe & Israel
People
Allan Jensen
Commercial Manager

Unlock access to complete

Funding Insights of Seqens

  • Total Funding
  • Total Rounds 3
  • Last Round
  • First Round
  • Investors Count 4
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2017 Amount Series A - Seqens Valuation Societe Generale Capital Partenaire
Jun, 2016 Amount Series A - Seqens Valuation Merieux Developement , Ardian
Jun, 2016 Amount Series A - Seqens Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Seqens

Seqens has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Eurazeo, Societe Generale Capital Partenaire and Merieux Developement. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Investor Description Founded Year Domain Location
Venture capital investments are managed by Societe Generale Capital Partenaire.
Founded Year Domain Location
Private equity and debt investments are managed across multiple sectors.
Founded Year Domain Location
-
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Seqens

Seqens has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include CELLforCURE and CU Chemie Uetikon. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Develops innovative technologies for cell and gene therapy products to advance medical treatments.
2010
Organic chemicals and pharmaceutical APIs are manufactured and distributed.
1970
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Seqens

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Seqens Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Seqens

Seqens operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Almac Group, Indoco Remedies, Concord Biotech, BDR Pharmaceuticals Internationals and Aurobindo Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Integrated CDMO services for biopharma R&D and manufacturing are offered.
domain founded_year HQ Location
APIs manufacturing and formulation services are provided in therapeutic segments.
domain founded_year HQ Location
APIs and enzymes are manufactured through fermentation by the CDMO.
domain founded_year HQ Location
APIs and finished products are developed and manufactured.
domain founded_year HQ Location
Generic biocatalytic solutions are provided for pharmaceutical applications.
domain founded_year HQ Location
APIs and peptides are developed and manufactured by Asymchem.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Seqens

Frequently Asked Questions about Seqens

When was Seqens founded?

Seqens was founded in 2003 and raised its 1st funding round 13 years after it was founded.

Where is Seqens located?

Seqens is headquartered in Ecully, France. It is registered at Ecully, Auvergne-rhone-alpes, France.

How many employees does Seqens have?

As of Apr 07, 2024, the latest employee count at Seqens is 39.

What is the annual revenue of Seqens?

Annual revenue of Seqens is $1.87M as on Mar 31, 2022.

What does Seqens do?

Seqens was established in 2003 in Ecully, France, as a provider of contract manufacturing services within the pharmaceutical and chemical sectors. Operations focus on the production of small molecules and peptides for clients seeking outsourced manufacturing solutions. Services encompass development, scale-up, and commercial production, with facilities supporting global supply chains. The company operates primarily from European locations, emphasizing regulatory compliance and quality standards in its processes.

Who are the top competitors of Seqens?

Seqens's top competitors include Concord Biotech, BDR Pharmaceuticals Internationals and Almac Group.

What products or services does Seqens offer?

Seqens offers APIs and Intermediates, Personal Care Ingredients, and Custom Specialty Ingredients.

How many acquisitions has Seqens made?

Seqens has made 2 acquisitions, including CELLforCURE, and CU Chemie Uetikon.

Who are Seqens's investors?

Seqens has 5 investors. Key investors include Eurazeo, Societe Generale Capital Partenaire, Merieux Developement, Ardian, and SK Capital.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available